Draft. Pending scientific and legal review. Not medical advice.
BrainGenomarkers · Neurology
BrainGenomarkers · Neurology groups genetic susceptibility panels for nervous-system disorders. They cover neurodegenerative, cerebrovascular and neurodevelopmental axes. They list associated variants; they do not diagnose on their own. Indication and interpretation belong to the healthcare professional.
Clinical scope
The catalogue includes NGS panels oriented, among others, to Alzheimer disease, Parkinson disease, cerebrovascular disease, ataxias, epilepsy and epileptic encephalopathy, migraine, ALS, movement disorders, neuromuscular conditions, neurodevelopmental disorders, intellectual disability and autism spectrum disorder.
Some entities also have a narrower genetic profile (for example Alzheimer disease, cerebrovascular disease or Parkinson disease) and, in clinical genetics, high-consequence single-gene tests (HTT, PSEN1/2, APP, SOD1, NOTCH3, ataxia expansions).
Catalogue panels and profiles
NGS panels in this line have different gene coverage by entity. Some axes (Alzheimer disease, cerebrovascular disease, Parkinson disease) also have a narrower genetic profile under genetic profiles. That difference in scope matters for the clinical question: the profile lists a smaller set of susceptibility genes; the panel widens the search.
Clinical genetics includes related single-gene tests (for example SNCA, SOD1, NOTCH3, HTT, PSEN1/2, APP and ataxia expansions). Having a profile, a panel and a single-gene test available does not mean they should be ordered together: the professional decides according to suspicion and care guidelines.
What it can and cannot provide
These panels may support etiological investigation or susceptibility assessment when the clinical question justifies it. They do not replace neurological examination, imaging or the rest of the clinical work-up.
Per the catalogue framework, associated-variant panels do not establish a diagnosis or an individual predictive value. Orphanet and GeneReviews provide context on rare diseases and associated genes; ClinGen helps assess gene validity. Which categories of findings are returned in broad sequencing is recorded in consent before the test.
Specific cautions
High-consequence presymptomatic tests (Huntington, PSEN1, PSEN2, APP, SOD1, ataxias, CADASIL) are not requested through the site form. They require a documented clinical indication and prior genetic counselling.
They may concern children. Consent is by representation, with a clinical indication. Predictive tests for adult-onset conditions are not intended in minors unless there is a direct clinical benefit, a judgement for the professional.
Pending
Pending Phase 0: operational data per panel (sample, turnaround, sensitivity) and verification of ambiguous gene symbols in lists. The name «BrainGenomarkers · Neurology» matches the catalogue and awaits formal laboratory confirmation.
